Literature DB >> 26614867

Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders.

Sarah Wall1, Jennifer A Woyach2.   

Abstract

Chronic lymphocytic leukemia affects less than 1% of US adults but is the most common leukemia and primarily affects older patients. Non-Hodgkin lymphomas are the seventh most common cancers in the United States and also primarily affect older patients. In general, older patients should be treated differently than their younger, fitter counterparts. Fitness level and comorbidities should be taken into account when planning treatment. First-line treatment of most of these B-cell lymphoproliferative disorders consists of chemoimmunotherapy. In relapsed and refractory disease, there is a growing role for therapies targeting the B-cell receptor signaling pathway.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Elderly; Non-Hodgkin lymphoma

Mesh:

Year:  2016        PMID: 26614867     DOI: 10.1016/j.cger.2015.08.006

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  5 in total

Review 1.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

2.  Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.

Authors:  C Owen; A S Gerrie; V Banerji; S Assouline; C Chen; K S Robinson; E Lye; G Fraser
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

3.  Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia.

Authors:  Abigail S Robbertz; David M Weiss; Farrukh T Awan; John C Byrd; Kerry A Rogers; Jennifer A Woyach
Journal:  Support Care Cancer       Date:  2019-07-22       Impact factor: 3.603

4.  Correlates of common concerns in older cancer survivors of leukemia and lymphoma: results from the WHI LILAC study.

Authors:  Kah Poh Loh; Eric M McLaughlin; Jessica L Krok-Schoen; Oreofe O Odejide; Areej El-Jawahri; Lihong Qi; Aladdin H Shadyab; Lisa G Johnson; Electra D Paskett
Journal:  J Cancer Surviv       Date:  2022-08-18       Impact factor: 4.062

5.  Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients.

Authors:  Guozhen Liu; Xiaoling Hu; Lei Gao; Zhenjun Feng
Journal:  Med Sci Monit       Date:  2017-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.